June 22, 2020 - The London School of Hygiene & Tropical Medicine (LSHTM) and ARCTEC have announced the launch of an early version of their Global Vector Hub (GVH), GVH-Beta. Read more
January 9, 2020 - Scientists and technicians working on arbovirus projects in Senegal and West Africa are meeting for a training workshop organized by the Mérieux Foundation and Institut Pasteur of Dakar from January 6-10, 2020. Read more
October 30, 2019 - The Global Birth Defects Description and Coding (GBDDC) app has just been released today. This first of its kind app provides images and definitions of major externally visible birth defects with ICD codes, in addition to ... Read more
October 28, 2019 - The Universidad del Valle hosted the annual ZikaPLAN meeting October 21-22, convening over 60 consortium members in Cali, Colombia. Read more
October 24, 2019 - The toolkit is based on guidelines developed by scientists funded by the EUHorizon2020 grant and the ZikaPLAN-supported IGOSZika project. Read more
Sonja E Leonhard et al. – Journal of Neurology Neurosurgery and Psychiatry, July 30, 2020
The SARS-CoV-2 pandemic is the last in line of several epidemics of infectious diseases that have been linked to the Guillain-Barré syndrome (GBS). As threats of epidemics of emerging infectious diseases persist, this is the time to learn from the past and to advance our response to future outbreaks in terms of research and management of GBS.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques.
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE).
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.